GRI GRI Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1824293 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY30.6%
TTM EPS YoY101.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-144.6%
ROA-107.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets9.8%
Debt / equity0.00x
Current ratio10.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.23x
Accruals ratio24.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $0 |
| R&D expense | $6.82M | $3.77M | $3.23M | $242,000 | $5.19M |
| SG&A expense | $5.16M | $4.47M | $8.15M | $2.00M | $4.07M |
| Operating income | -$11.98M | -$8.23M | -$11.39M | -$2.24M | -$9.26M |
| Income tax | $3,000 | $2,000 | — | — | — |
| Net income | -$11.96M | -$8.21M | -$13.04M | -$3.22M | -$9.30M |
| EBITDA | -$11.97M | -$8.23M | -$11.38M | -$2.24M | — |
| EPS (basic) | -121.80 | -1,545.55 | -5,018.09 | -24.95 | -1.42 |
| EPS (diluted) | -121.80 | -1,545.55 | -5,018.09 | -24.95 | -1.42 |
| Weighted avg. shares (diluted) | 98,162 | 6,547 | 2,598 | 128,994 | 6.54M |
| Balance sheet | |||||
| Cash & equivalents | $8.23M | $5.03M | $1.81M | $9,000 | $90,000 |
| Short-term investments | — | — | — | $0 | $3.81M |
| Current assets | $8.59M | $5.62M | $2.93M | $312,000 | $8.13M |
| PP&E, net | $3,000 | $4,000 | $8,000 | $4,000 | $0 |
| Total assets | $8.67M | $5.74M | $2.96M | $383,000 | $8.34M |
| Current liabilities | $2.64M | $1.64M | $2.70M | $1.99M | $2.44M |
| Total liabilities | $2.66M | $1.71M | $2.70M | $2.01M | $2.52M |
| Shareholders' equity | $6.01M | $4.03M | $259,000 | -$1.62M | -$4.85M |
| Shares outstanding | 497,693 | 18,768 | 2,909 | 142,820 | 6.81M |
| Cash flow statement | |||||
| Operating cash flow | -$10.19M | -$8.61M | -$8.99M | -$1.08M | -$8.31M |
| Capital expenditure | $3,000 | $0 | $8,000 | $3,000 | $0 |
| Free cash flow | -$10.19M | -$8.61M | -$9.00M | -$1.09M | -$8.31M |
| Investing cash flow | -$3,000 | $0 | -$8,000 | -$3,000 | -$3.84M |
| Financing cash flow | $13.39M | $11.83M | $10.80M | $1.01M | $15.75M |
| Depreciation & amortization | $4,000 | $4,000 | $4,000 | $3,000 | — |
| Stock-based compensation | $793,000 | $148,000 | $388,000 | $25,000 | $626,000 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.